News & Updates

Amblyopia protective against age-related macular degeneration

14 Jul 2023

Less amblyopic individuals are more likely to have age-related macular degeneratio n (AMD) diagnosed on the amblyopic eye than on the nonamblyopic eye, as reported in a study. Meanwhile, individuals with lateral asymmetry tend to have the more advanced form of AMD on the nonamblyopic eye.

Amblyopia protective against age-related macular degeneration

14 Jul 2023

On April 15, 2023, ZP Therapeutics held a scientific symposium entitled Taking Hope Further in HR+, HER2- Breast Cancer at the EDSA Shangri-La Hotel in response to the alarming trend of breast cancer being the most common type of cancer in the country, and to formally launch a new treatment option for breast cancer: Abemaciclib (Yulareb®).

14 Jul 2023

In the year 2020, 27,163 new cases of breast cancer were diagnosed in the Philippines and breast cancer accounted for 17.7% of all cancer cases, making it the most common type of cancer in the country.¹

On April 15, 2023, ZP Therapeutics held a scientific symposium entitled Taking Hope Further in HR+, HER2- Breast Cancer at the EDSA Shangri-La Hotel in response to this alarming trend, and to formally launch a new treatment option for breast cancer: Abemaciclib (Yulareb®). The event gathered over 100 industry experts and oncologists from across the country.

On April 15, 2023, ZP Therapeutics held a scientific symposium entitled Taking Hope Further in HR+, HER2- Breast Cancer at the EDSA Shangri-La Hotel in response to the alarming trend of breast cancer being the most common type of cancer in the country, and to formally launch a new treatment option for breast cancer: Abemaciclib (Yulareb®).

14 Jul 2023

PNH carries a high disease burden despite treatment

14 Jul 2023 by

Paroxysmal nocturnal haemoglobinuria (PNH) carries a substantial disease burden and healthcare resource utilization, even in patients already receiving treatment with C5 inhibitors, according to an expert who presented at EHA 2023.

PNH carries a high disease burden despite treatment

14 Jul 2023

Tranexamic acid use before CS reduces blood loss

14 Jul 2023 by

The use of prophylactic tranexamic acid (TXA) prior to elective Caesarean section (CS) led to significantly lower blood loss in women, particularly those at high risk for postpartum haemorrhage (PPH), according to a study presented at RCOG 2023.

Tranexamic acid use before CS reduces blood loss

14 Jul 2023

OSA treatment with positive airway pressure reduces economic burden in HFpEF

13 Jul 2023

In patients with heart failure with preserved ejection fraction (HFpEF) and comorbid obstructive sleep apnoea (OSA), positive airway pressure (PAP) therapy helps lower the use of healthcare resource, according to a study.

OSA treatment with positive airway pressure reduces economic burden in HFpEF

13 Jul 2023

QUIWI: FLT3 type II inhibitor confers survival advantage in acute myeloid leukaemia

13 Jul 2023 by

The FLT3 type II inhibitor quizartinib, when combined with induction and consolidated therapy and continued for up to 12 cycles, yields survival benefits such as prolonged overall and relapse-free survival in patients with newly diagnosed wild-type acute myeloid leukaemia (AML), as shown in the interim results of the phase II study QUIWI.

QUIWI: FLT3 type II inhibitor confers survival advantage in acute myeloid leukaemia

13 Jul 2023

Does acute kidney injury lead to CKD progression?

13 Jul 2023

Mild to moderate acute kidney injury (AKI) is slightly associated with worsening subsequent kidney function in patients with chronic kidney disease (CKD) following adjustments for pre-AKI estimated glomerular filtration rate (eGFR), proteinuria, and other covariables, with the possibility of no correlation, suggests a study.

Does acute kidney injury lead to CKD progression?

13 Jul 2023

Can cuffless wearable devices track BP changes?

13 Jul 2023 by

A cuffless wearable device may help improve hypertension management if it demonstrates accuracy and clinical utility. However, a recent study has found that a commercially available blood pressure (BP) monitoring device does not accurately track night-time BP decline and medication-induced BP changes.